Alcobra Pharma


Roth Capital Maintains Buy On Alcobra Following First Patient Enrollment In Fragile X Study

In a research report published today, Roth Capital analyst Debjit Chattopadhyay reiterated a Buy rating on Alcobra Pharma (NASDAQ:ADHD), following first patient enrollment in a phase IIb study on …

Alcobra Pharma: For Risk-Tolerant Investors, We Recommend Buying Shares, Says Roth Capital

In a research report published this morning, Roth Capital analyst Debjit Chattopadhyay reiterated a Buy rating on Alcobra Pharma (NASDAQ:ADHD) with a $40 price target …

Roth Capital Reiterates Buy On Alcobra On The Heels Of Fragile X Opportunity

In a research note published today, Roth Capital analyst Debjit Chattopadhyay reiterated a Buy rating on Alcobra Pharma (ADHD) with a $40 price target, as the company commenced patient …